-+ 0.00%
-+ 0.00%
-+ 0.00%

INmune Bio Announces New Neuroimaging Data From Phase 2 MINDFuL Trial Of XPro1595 In Patients With Early Alzheimer's Disease And Elevated Neuroinflammation

Benzinga·12/01/2025 13:07:18
Listen to the news

INmune Bio, Inc. (NASDAQ:INMB), a clinical-stage biotechnology company developing inflammation and immunology therapies targeting innate immune dysfunction, announces new neuroimaging data from its Phase 2 MINDFuL trial of XPro1595 in patients with early Alzheimer's disease (AD) and elevated neuroinflammation. The results will be presented at the 18th Clinical Trials on Alzheimer's Disease conference (CTAD), being held on December 1-4, 2025 in San Diego, CA.

The new analyses add to the growing body of clinical, biomarker, and imaging evidence supporting XPro1595's mechanism of selectively neutralizing soluble TNF (sTNF). The data further validate the Company's strategy of targeting inflammation-driven AD, a large, underserved subset representing a significant unmet need and potential commercial opportunity.